Guess which ASX biotech stock is surging 11% on big FDA news

Paradigm made a big step towards treating knee osteoarthritis.

| More on:
A group of people in a corporate setting do a collective high five.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are taking off on Wednesday.

In morning trade, the ASX biotech stock is up 11% to 29 cents.

Why is this ASX biotech stock surging?

Investors have been buying the late-stage drug development company's shares this morning after it made a big announcement.

According to the release, Paradigm has received a detailed response from the U.S. Food and Drug Administration (FDA) following the Type D meeting response submitted to the agency in April.

The company advised that the response from the FDA comprises a detailed set of comments that provides a pathway for progression of its phase 3 clinical program for knee osteoarthritis (OA).

What was the FDA's response?

The release reveals that the FDA has confirmed that Paradigm's phase 2 clinical data (PARA_005 and PARA_OA_008) supported the safety and tolerability of the twice weekly 2 mg/Kg dose, and that the clinical monitoring for adrenal effects will continue.

The regulator has also provided detailed guidance for the use of the company's selected dosing regimen of 2mg/kg injectable pentosan polysulfate sodium (iPPS) administered twice weekly.

Management believes this is a "significant outcome" for Paradigm. This is because it feels that based on the clinical data generated to date, with a dosing regimen of 2mg/kg iPPS administered twice weekly, the phase 3 clinical trial is best set up for success.

In addition to feedback on the dosing regimen, the FDA has provided feedback on amendments to the monitoring and mitigation plan, and statistical guidance. The good news is that management believes these changes were supported by clinical and nonclinical data generated in its clinical development programs to date. As a result, it intends to implement these changes and submit the updated protocol under the open Investigational New Drug (IND) application currently in place with the FDA.

Once the protocol is submitted, Paradigm expects a 30-day review period before proceeding with enrolment for the PARA_OA_012 trial.

'One step closer'

Commenting on the news, the ASX biotech stock's managing director, Paul Rennie, said:

I understand that many investors are eager to know the dosage that will be used in the pivotal phase 3 clinical trial. I am pleased to announce that the FDA has indicated our clinical data supports the safety and tolerability of the twice-weekly administration of 2 mg/kg, the same dosing regimen Paradigm used in its phase 2 clinical studies (PARA_005 and PARA_OA_008). We would like to extend our gratitude to the US FDA for their valuable guidance on the phase 3 protocol.

Paradigm's chief medical officer, Dr Donna Skerrett, added:

I believe the clarity provided by the FDA's response has brought us one step closer to entering the pivotal phase of the program. We now have a clearer and more certain path forward, enabling us to optimize the clinical protocol. We are incredibly proud of the collaborative efforts and hard work that have led us to this point, and we are excited to move forward with a protocol designed to maximise our chances of success. The alignment with the FDA's guidance further strengthens our confidence as we progress towards a successful outcome, bringing us closer to achieving our goal of securing approval for iPPS.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

2 ASX healthcare shares rocketing over 16% on Big US news

These companies are making their shareholders smile on Thursday. But why?

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Healthcare Shares

Should you buy CSL shares after recent weakness?

Does the dip present a buying opportunity?

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares up 25% in 2 days as Chemist Warehouse merger looks set

The deal continues to create tailwinds for Sigma shares.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

500 million reasons why ResMed shares are charging higher today

This growing company has big plans and is forecasting strong growth through to the end of the decade.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on

These companies have developed new drugs to treat vision loss and erectile dysfunction.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Guess which ASX 200 healthcare stock is up 12% on big Chemist Warehouse news

Investors appear to believe this news could be a sign that the deal will go ahead.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Up 630% this year AND profitable! This small ASX healthcare share is glowing

Why has this stock delivered incredible returns this year? Let's find out.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Can the CSL share price push back above $300?

The biotech last traded there on September 9.

Read more »